Troxerutin-Mediated Complement Pathway Inhibition is a Disease-Modifying Treatment for Inflammatory Arthritis

This study integrated computational pathway analysis with in vivo experimental confirmation to evaluate troxerutin as a disease-modifying treatment for inflammatory arthritis. Through targeted inhibition of the complement cascade, the work establishes a mechanism-driven therapeutic rationale and demonstrates disease-modifying activity in a preclinical model. It is the firm's flagship example of an integrated discovery-to-publication workflow owned end-to-end by one scientific lead.

This study integrated computational pathway analysis with in vivo experimental confirmation to evaluate troxerutin as a disease-modifying treatment for inflammatory arthritis. Through targeted inhibition of the complement cascade, the work establishes a mechanism-driven therapeutic rationale and demonstrates disease-modifying activity in a preclinical model. The integrated approach combined in silico target validation, complement-cascade pathway analysis, and in vivo confirmation in an inflammatory arthritis model. Results demonstrated significant disease-modifying activity with mechanism evidence positioning troxerutin as a promising candidate for further development. This represents the firm's flagship example of an integrated discovery-to-publication workflow owned end-to-end by one scientific lead.